Open Access

Health-related quality of life in Croatian general population and multiple myeloma patients assessed by the EORTC QLQ-C30 and EORTC QLQ-MY20 questionnaires

Sanja Ledinski Ficko
Sanja Ledinski Ficko
, 
Vlatko Pejsa
Vlatko Pejsa
 and 
Vesna Zadnik
Vesna Zadnik
   | Sep 24, 2019
Radiology and Oncology's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Research Article
Published Online: Sep 24, 2019
Page range: 337 - 347
Received: Jul 23, 2019
Accepted: Aug 09, 2019
DOI: https://doi.org/10.2478/raon-2019-0047
© 2019 Sanja Ledinski Ficko, Vlatko Pejsa, Vesna Zadnik, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

Summary score for EORTC QLQ-C30 in general population, initial testing and post-testing.
Summary score for EORTC QLQ-C30 in general population, initial testing and post-testing.

Mean score (MS) and standard deviations (SD) for all EORTC QLQ-C30 dimensions and scales by age for general population

40–49 50–59 60–69 70 and older p*
MS SD MS SD MS SD MS SD
Global health status/quality of life 69.1 18.6 71.1 20.7 67.4 19.9 56.9 23.9 .035
Physical functioning 86.2 12.9 83.9 16.9 81.8 21.7 61.2 30.2 .000
Role functioning 86.1 20.6 85.9 20.2 80.8 28.6 69.1 37.2 .128
Emotional functioning 71.9 22.4 78.2 19.7 78.6 19.7 66.7 26.4 .034
Cognitive functioning 80.6 21.7 85.7 17.8 85.6 17.4 80.8 26.3 .402
Social functioning 86.8 20.1 90.6 15.5 88.5 20.8 76.5 31.0 .049
Fatigue 33.7 20.8 28.0 22.7 29.5 22.8 43.8 29.2 .014
Nausea/vomiting 6.9 14.2 4.9 11.3 4.6 10.4 10.3 20.1 .276
Pain 25.8 24.3 23.3 24.5 24.1 27.8 40.2 32.3 .028
Dyspnoea 18.8 24.6 17.3 23.6 22.1 25.9 26.5 30.6 .362
Insomnia 24.4 28.7 26.3 30.2 30.7 30.5 41.2 37.7 .094
Appetite loss 6.9 15.2 5.3 13.7 8.2 15.6 24.5 34.1 .001
Constipation 8.2 18.0 8.3 19.2 13.8 21.9 14.7 28.7 .164
Diarrhoea 7.9 15.8 6.5 13.9 6.2 13.0 13.7 26.1 .595
Financial difficulties 7.6 17.7 7.4 17.7 14.4 26.9 22.5 33.6 .009
Summary score 83.1 12.5 85.8 12.2 82.9 15.0 72.6 23.7 .030

Mean score (MS) and standard deviation (SD) for all QLQ-MY20 scales in multiple myeloma (MM) patients before and after chemotherapy and transplantation

MM–before chemotherapy MM–after chemotherapy p* MM–before transplantation MM–after transplantation p*
MS SD MS SD MS SD MS SD
Future perspective 2.2 0.7 2.0 0.7 .285 2.2 0.7 1.8 0.7 .036
Body image 1.9 1.3 1.4 0.9 .023 1.4 0.6 1.4 0.6 1.00
Disease symptoms 1.9 0.6 2.2 0.6 .039 1.7 0.6 1.8 0.7 .571
Side effects of treatment 2.1 0.7 1.8 0.4 .361 1.9 0.6 1.5 0.3 .144

Correlation between dimensions and scales in the EORTC QLQ-C30 and QLQ-MY20 (chemotherapy)

FP BI DS SET GHS PF RF EF CF SF F NV P D I AL C DIA FD
FP 1 .369 .330* .395* -.213 -.254 -.443 -.478 -.057 -.410 .086 .149 .322* .119 -.104 .309* .004 .017 .264
BI .369 1 .208 .586 -.135 -.155 -.333* -.428 -.101 -.396 131 .299* .164 -.044 .107 .186 -.074 .229 .270
DS .330* .208 1 .669 -.459 -.678 -.429 -.369 -.545 -.400 .642 .289* .779 .255 -.127 .512 .150 .274 .243
SET .395* .586 .669 1 -.277 -.513 -.462 -.579 -.577 -.568 .560 .599 .482 .116 .305 .644 -.121 .451 .469
GHS -.213 -.135 -.459 -.277 1 .427 .341* .503 .336* .468 -.399 -.205 -.332* -.283* .013 -.528 -.033 -.489 -.335*
PF -.254 -.155 -.678 -.513 .427 1 .588 .367 .524 .430 -.807 -.277 -.725 -.337* .165 -.389 -.156 -.136 -.147
RF -.443 -.333* -.429 -.462 .341* .588 1 .384 .359* .491 -.564 -.373 -.554 -.376 -.094 -.449 -.113 -.259 -.316*
EF -.478 -.428 -.369 -.579 .503 .367 .384 1 .329* .692 -.266 -.616 -.408 .115 .048 -.596 -.117 -.424 -.414
CF -.057 -.101 -.545 -.577 .336* .524 .359* .329* 1 .176 -.625 -.383 -.502 -.170 -.088 -.424 .043 -.349* -.262
SF -.410 -.396 -.400 -.568 .468 .430 .491 .692 .176 1 -.225 -.498 -.353* -.134 .007 -.589 .064 -.304* -.534
F .086 .131 .642 .560 -.399 -.807 -.564 -.266 -.625 -.225 1 .272 .717 .456 .066 .374 .127 .369 .119
NV .149 .299* .289* .599 -.205 -.277 -.373 -.616 -.383 -.498 .272 1 .227 -.139 .083 .605 .125 .361* .317*
P .322* .164 .779 .482 -.332* -.725 -.554 -.408 -.502 -.353* .717 .227 1 .350* -.178 .389 .161 .222 .182
D .119 -.044 .255 .116 -.283* -.337* -.376 .115 -.170 -.134 .456 -.139 .350* 1 .204 .078 -.187 .206 .160
I -.104 .107 -.127 .305 .013 .165 -.094 .048 -.088 .007 .066 .083 -.178 .204 1 .238 -.186 .271 .194
AL .309* .186 .512 .644 -.528 -.389 -.449 -.596 -.424 -.589 .374 .605 .389 .078 .238 1 .000 .329* .375
C .004 -.074 .150 -.121 -.033 -.156 -.113 -.117 .043 .064 .127 .125 .161 -.187 -.186 .000 1 -.089 -.133
DIA .017 .229 .274 .451 -.489 -.136 -.259 -.424 -.349* -.304* .369 .361* .222 .206 .271 .329* -.089 1 .517
FD .264 .270 .243 .469 -.335* -.147 -.316* -.414 -.262 -.534 .119 .317* .182 .160 .194 .375 -.133 .517 1

Mean score (MS) and standard deviation (SD) for all EORTC QLQ-C30 dimensions and scales in multiple myeloma (MM) patients before and after chemotherapy and transplantation

MM–before chemotherapy MM–after chemotherapy p* MM–before transplantation MM–after transplantation p*
MS SD MS SD MS SD MS SD
Global health status/ quality of life 53.3 21.4 49.7 22.5 .283 64.4 15.7 74.7 18.0 .008
Physical functioning 53.9 26.3 38.9 21.3 .011 71.8 23.4 71.8 19.1 .955
Role functioning 50.7 39.8 46.7 31.9 .458 54.5 38.2 77.6 24.5 .009
Emotional functioning 73.3 27.6 78.0 21.9 .776 78.2 14.5 84.3 23.3 .107
Cognitive functioning 78.0 27.1 57.3 28.1 .007 86.0 14.9 91.0 14.3 .083
Social functioning 57.3 37.6 787 26.6 .007 62.8 30.7 78.0 26.1 .026
Fatigue 43.1 27.3 64.0 22.3 .001 39.1 21.5 40.2 24.6 .782
Nausea/vomiting 7.3 15.3 5.3 13.4 .603 7.7 12.7 0.0 0.0 .010
Pain 39.3 36.9 54.7 25.2 .039 37.2 30.3 31.4 28.0 .323
Dyspnoea 28.0 32.9 33.3 30.4 .590 26.9 26.7 17.9 23.5 .100
Insomnia 40.0 36.0 14.7 23.7 .010 23.1 27.9 20.5 31.4 .637
Appetite loss 28.0 38.1 21.3 35.8 .463 15.4 30.2 7.7 17.1 .286
Constipation 16.0 32.1 20.0 28.9 .564 11.5 18.7 1.3 6.5 .011
Diarrhoea 9.3 22.6 6.7 19.2 .414 10.3 18.3 1.3 6.5 .035
Financial diffuclities 41.3 41.1 14.7 28.9 .005 37.2 33.1 20.5 29.9 .018
Summary score 69.6 19.5 67.7 14.5 .181 76.0 15.7 83.3 9.7 .097

Correlation between dimensions and scales in the EORTC QLQ-C30 and QLQ-MY20 (transplantation)

FP BI DS SET GHS PF RF EF CF SF F NV P D I AL C DIA FD
FP 1 .451** .029 .289 -.383 -.246 -.203 -.499 -,106 -.333* .287* .238 -.035 .145 .296* .371 .309* .049 .053
BI .451 1 -.142 .026 -.109 -.047 -.009 -.083 ,105 .016 .038 -.006 -.151 -.048 .333* .109 .053 -.029 -.195
DS .029 -.142 1 .447 -.312* -.589 -.449 -.339* ,228 -.397 .527 -.051 .707 .406 .145 .035 -.060 -.072 .188
SET .289 .026 .447 1 -.615 -.710 -.627 -.397 -,299 -.455 .570 .597 .519 .642 .377* .523 .470 .485 .337*
GHS -.383 -.109 -.312* -.615 1 .629 .518 .349* ,159 .498 -.436 -.467 -.423 -.443 -.071 -.192 -.429 -.371 -.370
PF -.246 -.047 -.589 -.710 .629 1 .562 .403 ,147 .506 -.645 -.375 -.643 -.447 -.379 -.325* -.232 -.171 -.443
RF -.203 -.009 -.449 -.627 .518 .562 1 .346* -,015 .580 -.563 -.341* -.626 -.403 -.194 -.200 -.209 -.127 -.421
EF -.499 -.083 -.339* -.397 .349* .403 .346* 1 ,188 .378 -.347* -.217 -.146 -.191 -.395 -.120 -.123 -.054 -.258
CF -.106 .105 .228 -.299 .159 .147 -.015 .188 1 .024 -.002 -.348* .023 -.041 -.105 -.033 -.304* -.143 -.250
SF -.333* .016 -.397 -.455 .498 .506 .580 .378 ,024 1 -.539 -.245 -.376 -.178 -.188 -.078 -.158 -.080 -.292*
F .287* .038 .527 .570 -.436 -.645 -.563 -.347* -,002 -.539 1 .299* .563 .294* .423 .441 .154 .266 .336*
NV 238 -.006 -.051 .597 -.467 -.375 -.341* -.217 -,348* -.245 .299* 1 .258 .263 .197 .587 .660 .464 .299*
P -.035 -.151 .707 .519 -.423 -.643 -.626 -.146 ,023 -.376 .563 .258 1 .563 .077 .182 .188 .143 .376
D .145 -.048 .406 .642 -.443 -.447 -.403 -.191 -,041 -.178 .294* .263 .563 1 .149 .346* .190 .356 .178
I .296* .333* .145 .377* -.071 -.379 -.194 -.395 -,105 -.188 .423 .197 .077 .149 1 .398 .123 .264 .288*
AL .371** .109 .035 .523 -.192 -.325* -.200 -.120 -,033 -.078 .441 .587 .182 .346* .398 1 .271 .363 .148
C .309* .053 -.060 .470 -.429 -.232 -.209 -.123 -,304* -.158 .154 .660 .188 .190 .123 .271 1 .540 .152
DIA .049 -.029 -.072 .485 -.371 -.171 -.127 -.054 -,143 -.080 .266 .464 .143 .356 .264 .363 .540 1 .104
FD .053 -.195 .188 .337* -.370 -.443 -.421 -.258 -,250 -.292* .336* .299* .376 .178 .288* .148 .152 .104 1

Mean score (MS) and standard deviation (SD) for all EORTC QLQ-C30 dimensions and scales in general population and multiple myeloma (MM) patients at diagnosis at the time of setting the diagnosis

MM patients at diagnosis General population
MS SD MS SD P*
Global health status/ quality of life 58.9 19.4 68.2 20.6 .003
Physical functioning 63.0 26.2 81.7 20.1 .000
Role functioning 52.6 38.6 83.1 25.1 .000
Emotional functioning 75.8 21.7 75.1 21.6 .820
Cognitive functioning 82.0 22.0 83.5 20.1 .725
Social functioning 60.1 34.0 87.4 20.6 .000
Fatigue 41.0 24.3 31.9 23.4 .014
Nausea/vomiting 7.5 13.9 6.2 13.3 .346
Pain 38.2 33.4 26.1 26.5 .020
Dyspnoea 27.5 29.6 19.7 25.2 .078
Insomnia 31.4 32.9 28.3 30.9 .556
Appetite loss 21.6 34.5 8.5 18.7 .010
Constipation 13.7 25.9 10.1 20.8 .392
Diarrhoea 9.8 20.3 7.7 16.2 .712
Financial difficulties 39.2 36.9 10.6 22.6 .000
Summary score 72.9 17.8 83.0 14.8 .000
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed